Background Patients undergoing dialysis have a substantially increased risk of cardiovascular mortality and morbidity. Although several trials have shown the cardiovascular benefi ts of lowering blood pressure in the general population, there is uncertainty about the effi cacy and tolerability of reducing blood pressure in patients on dialysis. We did a systematic review and meta-analysis to assess the eff ect of blood pressure lowering in patients on dialysis.
Introduction
Worldwide, many hundreds of thousands of people receive dialysis on a continuing basis because of severe and irreversible chronic kidney disease. These patients are at increased risk of cardiovascular mortality and morbidity compared with the general population. 1 Every year, between 10% and 20% of all patients on dialysis die, with around 45% of these deaths attributed to cardiovascular causes. 2 Blood pressure is usually raised in patients receiving dialysis, possibly because the role of the kidneys in blood pressure homoeostasis is impaired; chronic volume overload and a range of other factors might also contribute to high blood pressure. Several clinical trials and meta-analyses [3] [4] [5] [6] [7] have shown the cardiovascular benefi ts of lowering blood pressure in the general population and in patients with early kidney disease; therefore, reduction of blood pressure is an attractive therapeutic target for patients on dialysis. However, the effi cacy and safety of lowering blood pressure in this patient population are still uncertain. Observational studies in patients on dialysis have suggested a timedependent association between blood pressure levels and cardiovascular outcomes, with low blood pressure being associated with higher mortality rates in the short term, but lower mortality rates in the long term. These fi ndings probably refl ect a confounding of the shortterm association attributable to reverse causation. 8, 9 Although most of the previous trials on blood pressure lowering have systematically excluded patients on dialysis, the fi rst trials done in this patient population reported confl icting results. 10, 11 We therefore undertook a systematic review and meta-analysis to assess the eff ect of treatments that reduce blood pressure in patients receiving maintenance dialysis.
Methods

Search strategy and selection criteria
We did a systematic review of the available literature in accordance with the QUORUM guidelines for the conduct of meta-analyses of intervention studies. 12 Relevant studies were identifi ed by searches of Medline via Ovid (from 1950 up to November, 2008), Embase (from 1966 up to November, 2008), and the Cochrane Library database (Cochrane Central Register of Controlled Trials; no date restriction), with relevant text words and medical subject headings that included all spellings of antihypertensive agents, "renal dialysis", "kidney failure", and "cardiovascular disease" (see webappendix p 3 for complete search strategy). The search was limited to randomised controlled trials but was without language restriction. Reference lists from identifi ed trials and review articles were manually scanned to identify any other relevant studies. A search of the ClinicalTrials.gov website was also done to identify randomised studies that were registered as completed but not yet published. Requests for original data were made by contacting authors or principal investigators.
The literature search, data extraction, and quality assessment were done independently by two reviewers (HJLH and TN) by use of a standardised approach. All completed randomised controlled trials that assessed the eff ects of agents that lower blood pressure on cardiovascular outcomes in adult patients on maintenance dialysis were eligible for inclusion. Outcomes analysed were all cardiovascular events, as defi ned by the authors of each study, all-cause mortality, and cardiovascular mortality.
Data extraction and quality assessment
The two reviewers extracted data on patient characteristics (age, sex, systolic and diastolic blood pressure, duration on dialysis, diabetes, hypertension, and heart failure status), follow-up duration, inclusion and exclusion criteria, rates of outcome events, type and dose of blood pressure lowering agent, mean diff erence in systolic and diastolic blood pressure during the trial, and summary measures of eff ects on outcomes of blood pressure treatment. The quality of the report was judged by concealment of treatment allocation, similarity of both groups at baseline in terms of prognostic factors, eligibility criteria, blinding of outcome assessors, completeness of follow-up, and intention-to-treat analysis. 13 We also used the Jadad score to quantify study quality. 14 Any disagreement in abstracted data was resolved by a third reviewer (VP).
Statistical analysis
Individual study risk ratios (RRs) and 95% CIs were calculated before data pooling. The weighted mean blood pressure reduction was calculated by multiplying the blood pressure diff erence in each study by the total number of patients in each study, and then dividing by the number of studies. Summary estimates of RRs were obtained by use of a random eff ects model. The percentage of variability across studies attributable to heterogeneity beyond chance was estimated by use of the I² statistic. 15 Potential publication bias was assessed with the Egger test and represented graphically by use of Begg funnel plots of the natural log of the RR versus its standard error. 16 Potential heterogeneity in estimates of treatment eff ect attributable to each potential source of heterogeneity was explored by univariate metaregression. 15 Additionally, we investigated possible sources of heterogeneity by comparing summary results obtained from subsets of studies grouped by number of events, duration of follow-up, patient status, and class of blood pressure lowering agent used. A two-sided p value of less than 0·05 was judged signifi cant for all analyses. All statistical analyses were done with STATA, version 9.
Role of the funding source
The sponsor had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all data in the study and had fi nal responsibility for the decision to submit for publication. Figure 1 shows how studies were selected. Seven randomised trials that provided information on a total of 1571 patients and 495 cardiovascular events were eligible for inclusion, 10, 11, [17] [18] [19] [20] [21] and one further randomised trial in 108 patients that reported a hazard ratio with confi dence intervals for cardiovascular events could also be included. 22 Six of the trials were published in peerreviewed journals 10, 11, 17, [19] [20] [21] and two were presented at international scientifi c meetings. 18, 22 Most other studies identifi ed by our search were randomised trials that provided information on intermediate clinical measures for cardiovascular disease, but no data on the outcomes as defi ned for our systematic review. Table 1 summarises the characteristics of the included randomised trials. Four trials were done in Europe, 10, 11, 18, 21 three in Japan, 19, 20, 22 and one in Hong Kong. 17 Of the eight trials, three assessed the eff ects of angiotensin-receptor blockers (ARBs), [18] [19] [20] two assessed an angiotensinconver ting enzyme (ACE) inhibitor, 11, 17 two a β blocker, 10, 22 Inclusion criteria Active treatment and one a calcium-channel blocker. 21 The mean baseline systolic blood pressure in the contributing studies ranged from 134 mm Hg to 155 mm Hg; for diastolic blood pressure the range was 75 mm Hg to 93 mm Hg. Three studies included patients on the basis of a diagnosis of hypertension; [19] [20] [21] the other fi ve studies enrolled patients with and without hypertension. The components of the cardiovascular composite endpoint diff ered across the studies. Myocardial infarction and cardiovascular mortality were the most frequently included components, three trials included hospital admission for heart failure as an endpoint, 11, 19, 22 and one trial included congestive heart failure. 20 Study follow-up period ranged from 12 months to 36 months. Six trials provided information about mean follow-up blood pressure diff erence between treatment groups. 10, 11, 17, 19, 20, 22 The weighted mean diff erence in blood pressure during follow-up between active and control treatment across all trials was -4·5 mm Hg for systolic and -2·3 mm Hg for diastolic blood pressure (fi gure 2). Quality assessment showed that few studies described concealment of allocation or blinding of outcome assessor. Two of the eight trials did not describe whether the analyses were by intention to treat (webappendix p 1). 20, 22 Across all published trials the mean Jadad score was 3·1 (maximum 5).
Results
Overall, treatment with blood pressure lowering drugs was associated with a lower risk of cardiovascular events compared with control regimens (RR 0·71, 95% CI 0·55-0·92; p=0·009; fi gure 2). Exclusion of the two unpublished trials did not alter the fi ndings (RR 0·64, 0·43-0·94; p=0·022) and there was no evidence of publication bias (Egger's test p=0·287; webappendix p 2).
There was evidence of heterogeneity in the magnitude of the eff ect across the included studies (I²=67·5%; p=0·003; figure 2). Figure 3 shows the results of the subgroup analyses. We identifi ed no evidence of heterogeneity of eff ect in all subgroup analyses (all values for heterogeneity p>0·068) apart from when studies were divided on the basis of inclusion or exclusion of hospital admission for heart failure in the composite endpoint (p=0·006). For every trial subgroup the point estimate of eff ect was suggestive of benefi t for this outcome. Univariate meta-regression analysis showed the presence of heterogeneity of eff ect by inclusion of heart failure in the composite outcome (p=0·006) and also suggested an eff ect of the number of events recorded in the trial (p=0·031) and the mean age of the trial participants (p=0·011). Exclusion of the trial that assessed peritoneal dialysis patients 17 did not substantially change the overall eff ect estimate (RR 0·70, 0·53-0·91).
Of the eight trials, seven studies (1571 patients) provided information on all-cause mortality and fi ve studies (1240 patients) provided information on cardiovascular mortality. The risks for all-cause mortality (RR 0·80, 0·66-0·96; p=0·014) and cardiovascular mortality (RR 0·71, 0·50-0·99; p=0·044) were lower for blood pressure lowering treatments than for control regimens (fi gure 4).
Numbers of events/patients
Active treatment Control
SBP/DBP difference (mm Hg)
Risk ratio (95% CI)
0·3
Favours active treatment There was no strong evidence of heterogeneity of eff ect size among the studies for the outcomes of all-cause mortality or cardiovascular mortality. Two studies used an active run-in design, in which patients who did not tolerate the study drug during a preliminary phase were not randomised to treatment or placebo. 10, 11 14% and 1% of patients were excluded during the run-in periods of these trials (table 2) . Five studies reported information about study treatment discontinuation rates. 10, 17, 18, 20, 21 Overall, the proportion of patients who stopped taking study medication was low and did not diff er substantially between active treatment and control groups (table 2).
Discussion
Individuals undergoing dialysis are at increased risk of death and cardiovascular events but so far no treatments proven to reduce this risk have been available to patients and clinicians. Interventions such as lipid lowering, 23 dialysis prescription modifi cation, 24 homocysteine lowering, [25] [26] [27] mineral metabolism modifi cation, 28 and haemoglobin normalisation 29 have been assessed in randomised trials and systematic reviews, but there is no clear evidence to show that any of these approaches reduces the risk of death or major cardiovascular events. In this meta-analysis of randomised trials, we have shown that treatment with agents that lower blood pressure reduces cardiovascular morbidity and mortality in patients on maintenance dialysis. The eff ects are consistent with or without the presence of hypertension and other comorbidities and across a range of drug classes.
The optimum blood pressure goals for dialysis patients have not been defi ned. The Kidney Disease Outcomes Quality Initiative recommends a predialysis blood pressure goal of below 140/90 mm Hg. 30 The rationale for this recommendation is largely based on extrapolation of blood pressure targets from studies done in the nondialysis population with normal renal function. Here, we found that the benefi t of blood pressure lowering drugs was similar in trials that did and did not select participants on the basis of raised baseline blood pressure levels.
Drugs that lower blood pressure might increase the risk of intradialytic hypotension, and previous observational studies have suggested that this adverse event might be associated with an increased risk of allcause mortality. 31 However, we found that blood pressure lowering was well tolerated, with few participants excluded during the active run-in phase of the two trials that used this design, and no consistent evidence of higher dropout rates in the active treatment groups than in the control groups of the studies. Additionally, the risk of death and other serious outcomes was reduced by the use of agents that lower blood pressure. Randomised controlled trials that compare the eff ects of diff erent intensities of blood pressure lowering on the risk of subsequent cardiovascular outcomes in patients on dialysis would provide further insight, but until further data are available, it would seem reasonable to consider treating patients on dialysis with some form of blood pressure lowering treatment, if they are able to tolerate the drug.
This analysis is not able to separate out the eff ects of blood pressure lowering for specifi c drug classes. The results do not show any diff erences in cardiovascular events caused by diff erent drug classes; however, the
Numbers of events/patients
Active treatment
All-cause mortality Li et al (2003) 17 Takahashi et al (2006) 19 Tepel et al (2008) 21 Cice et al (2003) 10 Suzuki et al (2008) 20 Nakao et al (2007) 22 Zannad et al (2006) 11 
Cice et al (2006) 18
Overall Test for heterogeneity: l 2 =30·0%, Q=8·57, p=0·20
Cardiovascular mortality
Li et al (2003) 17 Takahashi et al (2006) 19 Tepel et al (2008) 21 Cice et al (2003) 10 Suzuki et al (2008) 20 Nakao et al (2007) 22 Zannad et al (2006) 11 
Cice et al (2006) 18
Overall Test for heterogeneity: l 2 =54·6%, Q=8·8, p=0·07 statistical power to reliably compare drug classes was small. The data suggest that renin-angiotensin-system blockers, β blockers, and calcium-channel blockers are all suitable for use in patients on dialysis. Drugs such as α blockers and centrally acting agents should probably be viewed as secondary choices in the absence of randomised studies. Although the two studies of ACE inhibitors did not show benefi cial eff ects of this treatment, it is unlikely that these agents have diff erent eff ects from the other classes studied because the negative result came from a single trial and this result might have arisen by chance. Furthermore, ACE inhibitors have similar effi cacy to other drug classes, especially ARBs, in the general population. 32 Head-tohead studies that compare diff erent classes of blood pressure lowering agents have not been done in patients undergoing dialysis; however, trials in the general population have not shown markedly diff erent eff ects between drug classes. 5 In the absence of further data in patients on dialysis, the choice of blood pressure lowering agents should be made on the grounds of general tolerability, side-eff ect profi les, and other patient variables. Volume overload is an important contributor in the pathogenesis of high blood pressure in patients undergoing dialysis. Results from recent studies show that volume control in haemodialysis patients improves blood pressure control. 33 Since few data on the management of volume status during dialysis were provided by the trials investigated here, we were unable to assess the eff ect of this variable.
The blood pressure reduction achieved by patients varied widely among the trials. This variation might be related to the study population or class of drug used, but could also be the consequence of the variability in blood pressure measurement and the absence of fi rm criteria that defi ne how and when to measure blood pressure. Blood pressure is very sensitive to dialysis and variations in the timing of its measurement might lead to large diff erences in the reading recorded. The diff erences in blood pressure seen in the trials included in this analysis should therefore be interpreted with some caution.
The strengths of this systematic review and metaanalysis are the rigorous methodology, the importance of the clinical question, and the magnitude of the benefi ts seen. The limitations include the small number and size of the studies included, the limited statistical power of methods based on tabular data to investigate sources of heterogeneity, and our inability to obtain the full results of all completed studies.
Thus, treatment with agents that lower blood pressure should routinely be considered for patients undergoing dialysis to help prevent cardiovascular events and mortality. If our data are applied to a broad population of patients on dialysis with an annual mortality rate of about 10%, we calculate that blood pressure lowering treatment could prevent two of the ten deaths expected to occur in every 100 patients per year. This absolute benefi t will be greater for individuals at higher absolute risk, and is much greater than that reported for many other interventions in routine use.
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